Archive — US — techcrunch
Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, an AI drug discovery platform spun out from DeepMind, raised $600M from Thrive Capital to enhance its AI drug design engine and expedite clinical trials. Founded by Demis Hassabis, it leverages DeepMind's technology including AlphaFold. Last year, it formed partnerships with Eli Lilly and Novartis, potentially earning $3 billion in milestone payments. Hassabis emphasizes that funding will help recruit top scientists.
Key points
- Isomorphic Labs raised $600 million to develop its AI drug-discovery platform.
- The funding round was led by Thrive Capital with participation from GV and Alphabet.
- The money will be used to advance Isomorphic's drug design engine and support clinical trials.
- Founded by Demis Hassabis, Isomorphic is built on DeepMind's software, including AlphaFold.
- In 2023, Isomorphic Labs partnered with Eli Lilly and Novartis, with potential earnings of $3 billion.
- Hassabis stated the funding will allow Isomorphic to attract top research scientists.
Why it matters
- AI in drug discovery is a growing field, with potential to revolutionize pharmaceuticals.
- Funding in biotech has surged, reflecting a trend of increased investment in AI-driven health technologies.
- The use of DeepMind's AlphaFold signifies advancements in AI applications within life sciences.
Isomorphic Labs' significant funding round illustrates the increasing intersection of AI and healthcare, potentially transforming drug discovery processes and clinical trial efficiencies.